Journal of Cardiac Failure
Volume 15, Issue 3 , Pages 199-205, April 2009

Unconventional End Points in Cardiovascular Clinical Trials: Should We Be Moving Away From Morbidity and Mortality?

  • Jay Cohn, MD, FACC

      Affiliations

    • University of Minnesota, Minneapolis, Minnesota
    • Corresponding Author InformationReprint requests: Jay Cohn, MD, FACC, Cardiovascular Division, MMC 508, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455. Tel: 612-625-5646.
    • ,
  • John G.F. Cleland, MD, FACC

      Affiliations

    • Department of Cardiology, University of Hull, Kingston-upon-Hull, United Kingdom
    • ,
  • Jacobus Lubsen, MD, PhD

      Affiliations

    • SOCAR Research, Switzerland and Erasmust Medical Centre, Rotterdam, the Netherlands
    • ,
  • Jeffrey S. Borer, MD, FACC

      Affiliations

    • Weill Medical College of Cornell University, New York, New York
    • ,
  • Philippe Gabriel Steg, MD, FACC

      Affiliations

    • INSERM U-698, Paris, France
    • ,
  • Michael Perelman, MD

      Affiliations

    • Schering Plough, Kenilworth, New Jersey
    • ,
  • Faiez Zannad, MD

      Affiliations

    • Hypertension and Preventive Cardiology Division, Department of Cardiovascular Disease, Centre d'Investigations Cliniques INSERM-CHU, Nancy, France

Received 5 August 2008; received in revised form 22 October 2008; accepted 23 October 2008. published online 29 December 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Pfizer Inc. provided an unrestricted educational grant to CIC INSERM-CHU of Nancy, France, to support the workshop from which this manuscript was generated (coordinator: Faiez Zannad).

 Conflict of interest: None.

PII: S1071-9164(08)01053-1

doi:10.1016/j.cardfail.2008.10.029

Journal of Cardiac Failure
Volume 15, Issue 3 , Pages 199-205, April 2009

Article Tools

* Image Usage & Resolution